GENE ONLINE|News &
Opinion
Blog

2022-09-29| Trials & Approvals

Sanofi and Regeneron’s Dupixent Snags its Tenth Approval From the FDA

by Reed Slater
Share To
Dupixent, the monoclonal antibody jointly developed by Sanofi and Regeneron, is keeping its momentum going with its third FDA-approved indication this year and its tenth since 2017. The latest indication is reserved for adults with the chronic skin disease, prurigo nodularis, making it the first and only drug indicated for the disease. The FDA based its decision on two Phase 3 trials demonstrating clinically significant positive data. 

It's free! Log in now to read

LATEST
Innovative Cellular Mapping of BRCA-Related Breast Cancer Findings Reveals Novel Therapeutic Targets
2024-03-29
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top